Anti-CTLA-4 antibody primarily effects CD4+ T cells at the priming phase of the immune response, while anti-PD-1/PD-L1 acts predominantly on exhausted T cells within the tumour, which might be essential for overcoming the more immunosuppressive microenvironment in late-stage solid tumours. This evidence concerns the gene CD274 and neoplasm.